Survival rates finding

Active monitoring of PCa has the same high survival rates after 15 years as radiotherapy or surgery, reports the ProtecT trial, led by Bristol and Oxford Universities. Although men on active monitoring were more likely to see it progress or spread than those receiving radiotherapy or surgery, this didn’t reduce their likelihood of survival. The trial also found that the negative impacts of radiotherapy and surgery on urinary and sexual function persist much longer than previously thought – for up to 12 years. More here